NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00660504,Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00660504,,COMPLETED,"This study drug(Amrubicin)is believed to work by stopping the tumor cell in your body from growing. The purpose of this study is to evaluate the efficacy and safety of amrubicin with cisplatin compared to etoposide-cisplatin in the first-line treatment in extensive disease small cell lung cancer The subject, who is randomized to AP group may be involved into a pharmacokinetic study of amrubicin and the metabolites: amrubicinol voluntarily.",YES,Lung Cancer,DRUG: Amrubicin Hydrochloride|DRUG: Etoposide-Cisplatin combined chemotherapy,"Overall Survival, 1.5 years after last subject enrolled","Progression-Free Survival, 1.5 years after last subject enrolled|Objective Response Rate, Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR., participants were followed for the duration of the study, an average of 12 weeks","Overall Survival at 6 and 12 Months, 6 and 12 months.","Sumitomo Pharma (Suzhou) Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,300,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,D0750018|D0750018,2008-04,2012-02,2012-08,2008-04-17,2014-07-04,2014-07-18,"Fuzhou, Fujian, China|Lanzhou, Gansu, China|Guangzhou, Guangdong, China|Changsha, Hunan, China|Nanjing, Jiangsu, China|Nanchang, Jiangxi, China|Changchun, Jilin, China|Dalian/Shenyang, Liaoning, China|Shenyang, Liaoning, China|Xian, Shanxi, China|Chengdu, Sichuan, China|Hangzhou, Zhejiang, China|Beijing, China|Shanghai, China|Tianjin, China",
